Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000-2011.

Whop LJ, Baade P, Garvey G, Cunningham J, Brotherton JM, Lokuge K, Valery PC, O'Connell DL, Canfell K, Diaz A, Roder D, Gertig DM, Moore SP, Condon JR.

PLoS One. 2016 Apr 11;11(4):e0150473. doi: 10.1371/journal.pone.0150473. eCollection 2016.

2.

HPV vaccine impact in Australian women: ready for an HPV-based screening program.

Brotherton JM, Gertig DM, May C, Chappell G, Saville M.

Med J Aust. 2016 Mar 21;204(5):184-184e1. No abstract available.

PMID:
26985843
3.

Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia.

Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, Wrede CD, Heley S, Saville M, Gertig DM.

Int J Cancer. 2016 Jul 15;139(2):281-90. doi: 10.1002/ijc.30031. Epub 2016 Mar 10.

4.

Women's experience with home-based self-sampling for human papillomavirus testing.

Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, Wrede CD, Brotherton JM, Saville M, Gertig DM.

BMC Cancer. 2015 Nov 4;15:849. doi: 10.1186/s12885-015-1804-x.

5.

A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing.

Sultana F, Gertig DM, Wrede CD, English DR, Simpson JA, Drennan KT, Brotherton JM, Phillips G, Heley S, Castle PE, Saville M.

J Clin Virol. 2015 Aug;69:210-3. doi: 10.1016/j.jcv.2015.06.080. Epub 2015 Jun 19.

PMID:
26209409
6.

Women's views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting.

Sultana F, Mullins R, Murphy M, English DR, Simpson JA, Drennan KT, Heley S, Wrede CD, Brotherton JM, Saville M, Gertig DM.

Sex Health. 2015 Aug;12(4):279-86. doi: 10.1071/SH14236.

PMID:
26028338
7.

Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia.

Brotherton JM, Saville AM, May CL, Chappell G, Gertig DM.

Cancer Causes Control. 2015 Jun;26(6):953-4. doi: 10.1007/s10552-015-0568-6. Epub 2015 Mar 25. No abstract available.

PMID:
25804857
8.

Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.

Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, Jayasinghe Y, Gertig DM, Pitts MK, Garland SM; VACCINE Study group.

Vaccine. 2015 Jan 1;33(1):201-8. doi: 10.1016/j.vaccine.2014.10.045. Epub 2014 Nov 1.

PMID:
25444787
9.

Cervical screening rates for women vaccinated against human papillomavirus.

Budd AC, Brotherton JM, Gertig DM, Chau T, Drennan KT, Saville M.

Med J Aust. 2014 Sep 1;201(5):279-82.

PMID:
25163380
10.

Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia.

Sultana F, English DR, Simpson JA, Brotherton JM, Drennan K, Mullins R, Heley S, Wrede CD, Saville M, Gertig DM.

BMC Cancer. 2014 Mar 19;14:207. doi: 10.1186/1471-2407-14-207.

11.

High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: a cohort study with 10 years of follow-up.

Sultana F, English DR, Simpson JA, Canfell K, Gertig DM, Saville M.

Int J Cancer. 2014 Sep 1;135(5):1213-9. doi: 10.1002/ijc.28756. Epub 2014 Mar 13.

12.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

13.

The time-evolution of DCIS size distributions with applications to breast cancer growth and progression.

Dowty JG, Byrnes GB, Gertig DM.

Math Med Biol. 2014 Dec;31(4):353-64. doi: 10.1093/imammb/dqt014. Epub 2013 Jul 19.

PMID:
23873441
14.

Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).

Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, Wrede CD, Jayasinghe Y, Tan J, Gertig DM, Pitts M, Garland SM.

BMC Cancer. 2013 Jun 19;13:296. doi: 10.1186/1471-2407-13-296.

15.

Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria.

Barbaro B, Brotherton JM, Gertig DM.

Med J Aust. 2012 Apr 16;196(7):445. No abstract available.

PMID:
22509873
16.

Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening.

Kricker A, Disipio T, Stone J, Goumas C, Armes JE, Gertig DM, Armstrong BK.

Cancer Causes Control. 2012 Jan;23(1):89-102. doi: 10.1007/s10552-011-9858-9. Epub 2011 Oct 22.

PMID:
22020871
17.

Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact.

Brotherton JM, Gertig DM.

Expert Rev Anti Infect Ther. 2011 Aug;9(8):627-39. doi: 10.1586/eri.11.78. Review.

PMID:
21819329
18.

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM.

Lancet. 2011 Jun 18;377(9783):2085-92. doi: 10.1016/S0140-6736(11)60551-5.

PMID:
21684381
19.

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.

Gertig DM, Brotherton JM, Saville M.

Sex Health. 2011 Jun;8(2):171-8. doi: 10.1071/SH10001. Review.

PMID:
21592430
20.

Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia's role.

Garland SM, Brotherton JM, Fairley CK, Gertig DM, Saville M.

Sex Health. 2010 Sep;7(3):227-9. No abstract available.

PMID:
21058495
21.

Physical activity, body size and composition, and risk of ovarian cancer.

Chionh F, Baglietto L, Krishnan K, English DR, MacInnis RJ, Gertig DM, Hopper JL, Giles GG.

Cancer Causes Control. 2010 Dec;21(12):2183-94. doi: 10.1007/s10552-010-9638-y. Epub 2010 Sep 9.

PMID:
20827504
22.

HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis.

Allen KJ, Bertalli NA, Osborne NJ, Constantine CC, Delatycki MB, Nisselle AE, Nicoll AJ, Gertig DM, McLaren CE, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC; HealthIron Study Investigators.

Hepatology. 2010 Sep;52(3):925-33. doi: 10.1002/hep.23786.

23.

Using functional data analysis models to estimate future time trends in age-specific breast cancer mortality for the United States and England-Wales.

Erbas B, Akram M, Gertig DM, English D, Hopper JL, Kavanagh AM, Hyndman R.

J Epidemiol. 2010;20(2):159-65. Epub 2010 Feb 6.

24.

HFE C282Y homozygotes are at increased risk of breast and colorectal cancer.

Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, Anderson GJ, Southey MC, Olynyk JK, Powell LW, Hopper JL, Giles GG, English DR.

Hepatology. 2010 Apr;51(4):1311-8. doi: 10.1002/hep.23448.

25.

Influence of high-dose estrogen exposure during adolescence on mammographic density for age in adulthood.

Jordan HL, Hopper JL, Thomson RJ, Kavanagh AM, Gertig DM, Stone J, Venn AJ.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):121-9. doi: 10.1158/1055-9965.EPI-09-0434.

26.

A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis.

Constantine CC, Anderson GJ, Vulpe CD, McLaren CE, Bahlo M, Yeap HL, Gertig DM, Osborne NJ, Bertalli NA, Beckman KB, Chen V, Matak P, McKie AT, Delatycki MB, Olynyk JK, English DR, Southey MC, Giles GG, Hopper JL, Allen KJ, Gurrin LC.

Br J Haematol. 2009 Oct;147(1):140-9. doi: 10.1111/j.1365-2141.2009.07843.x. Epub 2009 Aug 10.

27.

HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity.

Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Nicoll AJ, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ; HealthIron Study Investigators.

Hepatology. 2009 Jul;50(1):94-101. doi: 10.1002/hep.22972.

28.

The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.

Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ; HealthIron Study Investigators.

Gastroenterology. 2008 Dec;135(6):1945-52. doi: 10.1053/j.gastro.2008.08.056. Epub 2008 Sep 13.

PMID:
18848943
29.

Using mammographic density to improve breast cancer screening outcomes.

Kavanagh AM, Byrnes GB, Nickson C, Cawson JN, Giles GG, Hopper JL, Gertig DM, English DR.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2818-24. doi: 10.1158/1055-9965.EPI-07-2835.

30.

Why do large breast cancers still present in a population offered screening?

Kricker A, Newman B, Gertig DM, Goumas C, Armes J, Armstrong BK.

Int J Cancer. 2008 Dec 15;123(12):2907-14. doi: 10.1002/ijc.23829.

31.

SNP selection for genes of iron metabolism in a study of genetic modifiers of hemochromatosis.

Constantine CC, Gurrin LC, McLaren CE, Bahlo M, Anderson GJ, Vulpe CD, Forrest SM, Allen KJ, Gertig DM; HealthIron Investigators.

BMC Med Genet. 2008 Mar 20;9:18. doi: 10.1186/1471-2350-9-18.

32.

Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.

Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE.

Cancer. 2008 Mar 1;112(5):1169-77. doi: 10.1002/cncr.23275.

33.

Iron-overload-related disease in HFE hereditary hemochromatosis.

Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM.

N Engl J Med. 2008 Jan 17;358(3):221-30. doi: 10.1056/NEJMoa073286.

34.

Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis.

Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM, Webb PM; Australian Cancer Study Group (ovarian cancer); Australian Ovarian Cancer Study Group.

Int J Cancer. 2008 Apr 1;122(7):1598-603.

35.

A comparison of different methods for including 'age at menopause' in analyses of the association between hormone replacement therapy use and breast cancer.

Simpson JA, English DR, Macinnis RJ, Gertig DM, Hopper JL, Giles GG.

J Fam Plann Reprod Health Care. 2007 Jan;33(1):11-6.

36.

Body size and composition and risk of rectal cancer (Australia).

MacInnis RJ, English DR, Haydon AM, Hopper JL, Gertig DM, Giles GG.

Cancer Causes Control. 2006 Dec;17(10):1291-7.

PMID:
17111261
37.

Urban-rural differences in the management of screen-detected invasive breast cancer and ductal carcinoma in situ in victoria.

Kok DL, Chang JH, Erbas B, Fletcher A, Kavanagh AM, Henderson MA, Gertig DM.

ANZ J Surg. 2006 Nov;76(11):996-1001.

PMID:
17054549
38.

Hormone therapy and breast cancer: what factors modify the association?

Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG.

Menopause. 2006 Mar-Apr;13(2):178-84.

PMID:
16645531
39.

A comparison of estradiol levels between women with a hysterectomy and ovarian conservation and women with an intact uterus.

Simpson JA, MacInnis RJ, English DR, Gertig DM, Morris HA, Giles GG.

Climacteric. 2005 Sep;8(3):300-3.

PMID:
16390762
40.

Determinants of false positive recall in an Australian mammographic screening program.

Kavanagh AM, Davidson N, Jolley D, Heuzenroeder L, Chapman A, Evans J, Gertig DM, Amos A.

Breast. 2006 Aug;15(4):510-8. Epub 2005 Nov 8.

41.

Forecasting age-specific breast cancer mortality using functional data models.

Erbas B, Hyndman RJ, Gertig DM.

Stat Med. 2007 Jan 30;26(2):458-70.

PMID:
16217849
42.

Dietary carbohydrate, fibre, glycaemic index, glycaemic load and the risk of postmenopausal breast cancer.

Giles GG, Simpson JA, English DR, Hodge AM, Gertig DM, Macinnis RJ, Hopper JL.

Int J Cancer. 2006 Apr 1;118(7):1843-7.

43.

Body size and composition and colon cancer risk in women.

MacInnis RJ, English DR, Hopper JL, Gertig DM, Haydon AM, Giles GG.

Int J Cancer. 2006 Mar 15;118(6):1496-500.

44.

Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study.

Baglietto L, English DR, Gertig DM, Hopper JL, Giles GG.

BMJ. 2005 Oct 8;331(7520):807. Epub 2005 Aug 8.

45.

CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.

Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB.

Breast Cancer Res. 2005;7(4):R513-21. Epub 2005 May 12.

46.

The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.

Montgomery KG, Chang JH, Gertig DM, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG.

Breast Cancer Res. 2005;7(3):R353-6. Epub 2005 Mar 4.

47.

Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis.

Fletcher AS, Erbas B, Kavanagh AM, Hart S, Rodger A, Gertig DM.

Breast. 2005 Jun;14(3):192-200. Epub 2005 Jan 8.

48.

Hormone replacement therapy, percent mammographic density, and sensitivity of mammography.

Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1060-4.

49.

Body size and composition and risk of postmenopausal breast cancer.

Macinnis RJ, English DR, Gertig DM, Hopper JL, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2117-25.

50.

Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?

Erbas B, Amos A, Fletcher A, Kavanagh AM, Gertig DM.

Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1569-73.

Supplemental Content

Loading ...
Support Center